Mindful Health Solutions’ Post

The beginning of Dr. Anthony Bossis' journey: "I think like a lot of kids, I had fear of death. I would lie in bed at night, between 7 and 10 years of age, and try to imagine what would happen after I died. And try to imagine that nothingness, and do this kind of thing in my head, of imagining nothingness forever and ever and ever. Until, of course, that created mental distress for me." A quote from The Terror and the Ecstasy of Psychedelics Part of a 13 minute audio of Dr. Anthony Bossis, posted on To the Best of Our Knowledge Link to hear audio: https://buff.ly/43a1lIJ Anthony P. Bossis, Ph.D. is a clinical psychologist and clinical assistant professor of psychiatry at NYU School of Medicine conducting FDA-approved clinical research with the psychedelic compound psilocybin since 2009. He was director of palliative care research and co-principal investigator on the landmark 2016 clinical trial and publication demonstrating a significant reduction in emotional distress from a single psilocybin session in persons with cancer. Anthony is on the faculty of The Center for Psychedelic Therapies and Research at the California Institute of Integral Studies in San Francisco, CA. and teaches for The Integrative Thanatology Certificate Training Program at the Art of Dying Institute in NYC. Link to Anthony Bossis at NYU https://buff.ly/3QjBius Photo credit: Seen on Psychedelic Assembly's post about a sold out event at the Athenaeum with Anthony Bossis @tothebestofourknowledge (on Instagram) @psychedelic_assembly (on Instagram) @psychedelicsanddeath (on Instagram) #gooddeath #PTSD #endoflife #Psychedelic #DrAnthonyBossis #AnthonyBossis #anxiety #Psilocybin #endoflifecare #facingdeath #psychiatry #Psychedelics #deatheducation #deatheducator #deathanddying #depression #cancerawareness #psychedelictherapist #psychedelicstudies

The beginning of Dr. Anthony Bossis' journey: "I think like a lot of kids, I had fear of death. I would lie in bed at night, between 7 and 10 years of age, and try to imagine what would happen after I died. And try to imagine that nothingness, and do this kind of thing in my head, of imagining nothingness forever and ever and ever. Until, of course, that created mental distress for me." A quote from The Terror and the Ecstasy of Psychedelics Part of a 13 minute audio of Dr. Anthony Bossis, posted on To the Best of Our Knowledge Link to hear audio: https://buff.ly/43a1lIJ Anthony P. Bossis, Ph.D. is a clinical psychologist and clinical assistant professor of psychiatry at NYU School of Medicine conducting FDA-approved clinical research with the psychedelic compound psilocybin since 2009. He was director of palliative care research and co-principal investigator on the landmark 2016 clinical trial and publication demonstrating a significant reduction in emotional distress from a single psilocybin session in persons with cancer. Anthony is on the faculty of The Center for Psychedelic Therapies and Research at the California Institute of Integral Studies in San Francisco, CA. and teaches for The Integrative Thanatology Certificate Training Program at the Art of Dying Institute in NYC. Link to Anthony Bossis at NYU https://buff.ly/3QjBius Photo credit: Seen on Psychedelic Assembly's post about a sold out event at the Athenaeum with Anthony Bossis @tothebestofourknowledge (on Instagram) @psychedelic_assembly (on Instagram) @psychedelicsanddeath (on Instagram) #gooddeath #PTSD #endoflife #Psychedelic #DrAnthonyBossis #AnthonyBossis #anxiety #Psilocybin #endoflifecare #facingdeath #psychiatry #Psychedelics #deatheducation #deatheducator #deathanddying #depression #cancerawareness #psychedelictherapist #psychedelicstudies

A Path to a Brighter Tomorrow 🔷 🔹 🔵 If you're seeking quality mental health care, Boston Neurobehavioral Associates is here to walk alongside you on your path to a brighter tomorrow. Don't hesitate to reach out to our compassionate team. Your journey to healing and happiness starts here. #mentalhealth #behavioralhealth #psychiatry #psychology

Talnt 🧠 The resurgence of interest in psychedelics for mental health therapy is a fascinating development in the field of psychiatry. This approach, which was largely sidelined since the mid-20th century, is now gaining renewed attention for its potential in treating conditions like depression and PTSD. Here's a closer look at the current research, regulatory status, and societal implications: 🔬 Current Research: Recent studies have shown promising results in using psychedelics such as psilocybin (found in magic mushrooms) and MDMA (commonly known as ecstasy) to treat various mental health disorders. Psilocybin has been found to reduce symptoms of depression significantly in several clinical trials, while MDMA has shown efficacy in phase 3 trials for treating PTSD. These substances are believed to help "reset" the brain's activity patterns, potentially offering relief where other treatments have failed. 🏛️ Regulatory Status: The regulatory landscape for psychedelic-assisted therapy is evolving. In the United States, the FDA has granted "breakthrough therapy" designation to psilocybin for depression and MDMA for PTSD, expediting the development and review process for these drugs. However, these substances are still generally classified as Schedule I drugs under federal law, indicating a high potential for abuse and no accepted medical use, which complicates their path to clinical use. 🌐 Societal Implications: The potential integration of psychedelics into mainstream mental health treatment is generating a broad discussion about their impact on society. While there is optimism about their therapeutic potential, concerns remain about the risks of misuse, the need for proper regulatory frameworks, and the cultural acceptance of these once-stigmatized substances. Advocates emphasize the importance of controlled, supervised therapeutic settings to mitigate risks and maximize benefits. 🔄 The re-emergence of psychedelics in mental health therapy represents a significant shift in the treatment landscape, potentially offering new hope for millions of people with chronic mental health issues. As research progresses, it will be crucial to navigate the ethical, regulatory, and practical challenges that accompany the therapeutic use of these powerful substances. #MentalHealth #PsychedelicTherapy #Psilocybin #MDMA #DepressionTreatment #PTSDTherapy #FDA #BreakthroughTherapy #Psychiatry #HealthcareInnovation

📢 Excited to share that our latest article, co-authored with Vedat Verter and Gustavo Turecki, titled “Impact of Psychiatric Follow-Up Frequency on Outcomes and Waiting Times,” has been published in AJMC - The American Journal of Managed Care! 📚🔍🎉 You can access it for free online. Our findings reveal that while naturally occurring variations in appointment frequencies may not significantly impact clinical outcomes, they do play a crucial role in affecting waiting times. Let’s continue advancing research in mental health! 💙🧠 #PsychiatryResearch #Healthcare #MentalHealth #ResearchPublication

Mental Health Screening Market to Grow $1.8 Billion by 2029 Download Sample PDF Report-https://lnkd.in/dM3y7JXk The global mental health screening market's revenue was estimated to be worth $0.9 billion in 2023 and is poised to reach $1.8 billion by 2029, growing at a CAGR of 12.2% from 2023 to 2029. Companies Working in the Market Avegen     Tata MD GAMA Healthcare      Hiwell South London and Maudsley NHS Foundation Trust      Infiheal East London NHS Foundation Trust The Burnt Chef Project   LloydsPharmacy   Self Space The Royal College of Psychiatrists     Voyage Care Ltd Central and North West London NHS Foundation Trust      St Andrew's Healthcare   Kaha Mind Paws in Work  Nurseplus UK Ltd    NELFT NHS Foundation Trust      Acacium Group The LightHouse Arabia The Tavistock and Portman NHS Foundation Trust      American Center for Psychiatry and Neurology      Lifeways Group  O7 Therapy  West London NHS Trust Heart It Out Karma Care HCL Healthcare   Camali Clinic Somerset NHS Foundation Trust Leeds and York Partnership NHS Foundation Trust      Mersey Care NHS Foundation Trust Social Worker Lewisham and Greenwich NHS Trust      Berkshire Healthcare NHS Foundation Trust   Madeeda Hospitals CareTech Tulasi Healthcare      The Cambian Group      Sussex Partnership NHS Foundation Trust     

"The Big Elephant in Gastroenterology: Mental Health Refocus" In the realm of gastroenterology, numerous clinical challenges intertwine with psychosocial elements. These factors not only impact patient prognosis but also play a significant role in shaping the doctor-patient dynamic, often introducing tensions. Embracing psychosomatic gastroenterology doesn't entail gastroenterologists becoming therapists or psychiatrists. Instead, it encourages us to transcend the confines of the biomedical or traditional psychiatric models. By incorporating insights from psychology and psychiatry, we can enhance our clinical approaches, fostering better outcomes for our patients. It's imperative to shift away from a purely biological perspective and embrace a more holistic approach that integrates biological, social, and psychological facets into gastroenterological practice. What's needed now is a comprehensive, interdisciplinary framework that acknowledges the multifaceted nature of gastroenterological care, paving the way for more effective strategies and improved patient well-being. https://lnkd.in/gRv3FDdP.

🧠 Long-Term Impact of COVID-19 on Cognitive and Psychiatric Health ➡️Read more: https://bit.ly/3AjOqLa 🔍A recent study has unveiled concerning findings: cognitive and psychiatric issues persist in COVID-19 patients two to three years post-infection. 🔬Researchers have identified long-lasting effects on the brain, which include memory loss, difficulty concentrating, anxiety, depression, and other mental health challenges. This discovery underscores the importance of ongoing support and treatment for those affected by COVID-19, even long after recovery from the acute phase of the illness. 📚 The findings emphasize the critical need for comprehensive care strategies that consider the lingering impact of COVID-19 on mental health. 🌐 Read the full study to understand the implications for your practice and stay informed about the latest developments in post-COVID care. Credit: The Lancet Psychiatry #COVID19 #MentalHealth #Cognitive #MedicalResearch #PatientCare #meded #eMednews

Interesting read: The economic burden of untreated OCD!

Embark on a transformative journey into the fascinating realm of metabolic psychiatry with our newest training: Metabolism and the Mind: A metabolic approach to treating psychiatric diseases. This comprehensive training will empower healthcare practitioners with the knowledge and expertise necessary to comprehend and address the metabolic complexities underlying mental health disorders. From mood disorders to addiction and neurodevelopmental conditions, our esteemed speakers will dissect various facets of metabolic psychiatry, and creating evidence-based strategies for diagnosis, treatment, and holistic management. ‣ Develop a comprehensive understanding of the metabolic determinants influencing psychiatric disorders ‣ Discover the therapeutic potential of ketogenic diets in the treatment of mood disorders, binge eating disorders, addiction, and more ‣ Explore cutting-edge research and clinical insights on metabolic interventions for mental health enhancement ‣ Acquire practical tools and methodologies for seamlessly integrating metabolic approaches into personalized treatment plans ‣ Foster interdisciplinary collaboration to deliver holistic care that addresses both metabolic and psychiatric dimensions of health Take the first step towards advancing mental health care and elevate your practice to new heights! Enroll today and get a 20% discount - https://bit.ly/3TFa3eF Nutrition Network #MetabolicPsychiatry #EarlyBirdOffer